The Quantellect read.As of Nov 19, 2026, 5 active firms cover Vaxcyte Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $89.00 to $130.00, a moderate spread. The average target of $117.20 sits 100% above the current $58.55. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 2 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.66 next quarter toward $-6.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$117.20
+100.2% upside
Average target across 5 active firms as of Nov 19, 2026 vs $58.55 current
Highest Target$130.00
Average Target$117.20
Lowest Target$89.00
Detailed analyst forecasts for PCVX
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 5 of 5 active firms rate PCVX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PCVX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.66
Range $-2.00 – $-0.97 · 3 analysts · -28% YoY
Next period, 3 analysts expect Vaxcyte Inc to earn $-1.66 a share (range $-2.00 – $-0.97), versus $-2.30 a year earlier. Full-year consensus is $-7.87, growing to $-6.87 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Vaxcyte Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PCVX.
#1
Roger Song
Jefferies · Rank #122
Buy
$146.00+149.4% to target
Overall win rate
43%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #160
Buy
$146.00+149.4% to target
Overall win rate
47%
+ Follow
#3
Joseph Stringer
Needham · Rank #256
Buy
$122.00+108.4% to target
Overall win rate
36%
+ Follow
#4
Thomas Shrader
BTIG · Rank #553
Buy
$89.00+52.0% to target
Overall win rate
32%
+ Follow
#5
Seamus Fernandez
Guggenheim
Buy
$125.00+113.5% to target
Coverage
—
+ Follow
PCVX stock forecast FAQ
What is PCVX's average 12-month price target?+
The 5 active firms with a live target average $117.20 for Vaxcyte Inc over the next 12 months, ranging from a $130.00 high to a $89.00 low, as of Nov 19, 2026.
Is PCVX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PCVX?+
The Street-high target is $130.00 (B of A Securities), and the Street-low is $89.00 (BTIG). The average of all 5 active-firm targets is $117.20.
How many active Wall Street firms cover PCVX?+
5 active firms have a recognized rating on Vaxcyte Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PCVX?+
Among analysts who currently cover PCVX, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $146.00 target.
What is Vaxcyte Inc's projected EPS for next quarter?+
The consensus estimate is $-1.66 per share (range $-2.00 – $-0.97) across 3 analysts. Full-year EPS is projected at $-7.87, rising to $-6.87 the following year.
How much revenue is Vaxcyte Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PCVX lately?+
As of Nov 19, 2026, 5 of 5 active firms rate PCVX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PCVX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.